Bayer to Expand Companion Animal Portfolio With Two New EU Product Approvals

First Launches in Germany and Austria to Follow Shortly

MONHEIM, Germany, April 26, 2011 - Bayer today announced that the European Commission has approved two new
companion animal products: Veraflox(R) (pradofloxacin) and Procox(R)
(emodepside and toltrazuril). Veraflox(R) is the first next-generation
veterinary fluoroquinolone antibiotic for the treatment of bacterial
infection in cats and dogs. Procox(R) is the first and only licensed
combination treatment for roundworm and coccidia in dogs.

"Bayer Animal Health is proud to introduce these two innovative
treatments which will provide veterinarians with much needed, effective new
treatment options for a range of indications," said Jean-Luc Lowinski,
Managing Director of Bayer Animal Health. "As an expert solution provider for
animal health we have a strong and ongoing commitment to researching and
developing innovative ways to address parasitic and bacterial infections in
companion animals."

Veterinary antibiotics such as fluoroquinolones are an essential weapon
in the fight against infections in companion animals worldwide. There have,
however, been no major advances in the class since the introduction of the
first veterinary fluoroquinolone by Bayer Animal Health over 20 years ago.

Veraflox(R) is the first next-generation veterinary fluoroquinolone
antibiotic for the treatment of bacterial infection in cats and dogs and
marks the first major advance in the fluoroquinolone market in many years.
Veraflox(R)'s mode of action gives it enhanced antibacterial activity
compared with existing fluoroquinolones, including extended spectrum efficacy
against Gram-positive and anaerobic pathogens. The European Commission
granted approval for the treatment of the following infections caused by
specified and susceptible pathogens: wound infections, superficial and deep
pyoderma (bacterial skin infections), acute urinary tract infections, and, as
adjunctive treatment for severe gingival (gum) and periodontal tissue
infections in dogs, and against wound infections, abscesses and acute upper
respiratory tract infections in cats (oral suspension). Veraflox is approved
in 30 European countries and will be launched in the first markets shortly.

Procox(R) is the first parasiticide of its kind for the combination
treatment of roundworm and coccidia gastrointestinal parasitic infections in
dogs, including puppies of at least two weeks of age and weighing at least
0.4 kg. This is important as puppies are extremely susceptible to parasitic
infections in their early months. Roundworms are often transmitted from the
mother to the newborn, and coccidia frequently occur during the first month
of life. Due to its single dose suspension formulation, which can be taken
from two weeks of age, Procox(R) offers an easy and convenient first time
treatment option for puppies.

Procox(R) is approved in 27 EU countries and the first launches are
planned for quarter 3, 2011.

About Veraflox(R)

Veraflox(R) has proven outstanding efficacy across a range of infections
in both cats and dogs. Veraflox(R) is safe and well tolerated at the
recommended therapeutic dose. In field studies of over 700 dogs and cats, all
adverse events with Veraflox(R) treatment were mild and transient and
comparable to the control group. Extensive ocular safety testing has
demonstrated that Veraflox(R) has no adverse effects on feline retinas, even
at ten times the recommend therapeutic dose. Veraflox(R) is palatable with
simple once daily formulations - flavoured tablets for dogs and cats and a
convenient oral suspension for cats - helping facilitate compliance whilst
giving veterinarians optimal and flexible control over infections. Unlike
long-acting injectable antibiotics, veterinarians are able to fully control
treatment duration with Veraflox(R) as it is administered daily.

About Procox(R)

Procox(R) is the first parasiticide of its kind for the combination
treatment of roundworm and coccidia gastrointestinal parasitic infections in
dogs. It treats infections with adult, immature adult and larval stages of
Toxocara canis and adult stages of Uncinaria stenocephala and Ancylostoma
caninum. In addition Procox(R) is effective against the replication of
coccidia and also against the shedding of oocysts, thereby reducing the
spread of infection. Procox(R) is available in an easy and convenient oral
suspension. One administration is generally sufficient though it can be given
every two weeks, on up to five occasions if required.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the
fields of health care, nutrition and high-tech materials. Bayer HealthCare, a
subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one
of the world's leading, innovative companies in the healthcare and medical
products industry and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and
manufacture products that will improve human and animal health worldwide.
Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010)
and is represented in more than 100 countries. Find more information at
www.bayerhealthcare.com.

With a turnover of EUR 1.120 million (2010) Bayer HealthCare's Animal
Health Division is one of the world's leading manufacturers of veterinary
drugs. The division manufactures and markets more than 100 different
veterinary drugs and care products for livestock and companion animals.

Find more information at www.animalhealth.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no
liability whatsoever to update these forward-looking statements or to conform
them to future events or developments.

Contact: Kathrin Statz, Tel. +49-2173-38-4019, E-Mail: kathrin.statz at bayer.com